WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002002099) PHARMACEUTICAL COMBINATION OF AN ANTI-ANDROGEN AND TAMOXIFEN FOR PROVIDING AN ANTI-ANDROGENIC EFFECT AND AROMATASE INHIBITION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/002099    International Application No.:    PCT/SE2001/001548
Publication Date: 10.01.2002 International Filing Date: 04.07.2001
Chapter 2 Demand Filed:    11.01.2002    
IPC:
A61K 31/138 (2006.01), A61K 31/167 (2006.01), A61K 31/4166 (2006.01), A61K 31/57 (2006.01)
Applicants: ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE) (For All Designated States Except US).
COCKSHOTT, Ian [GB/GB]; (GB) (For US Only).
FURR, Barrington [GB/GB]; (GB) (For US Only)
Inventors: COCKSHOTT, Ian; (GB).
FURR, Barrington; (GB)
Agent: GLOBAL INTELLECTUAL PROPERTY; Astrazeneca AB S-151 85 Södertälje (SE)
Priority Data:
0016428.5 05.07.2000 GB
0020767.0 24.08.2000 GB
Title (EN) PHARMACEUTICAL COMBINATION OF AN ANTI-ANDROGEN AND TAMOXIFEN FOR PROVIDING AN ANTI-ANDROGENIC EFFECT AND AROMATASE INHIBITION
(FR) COMBINAISON PHARMACEUTIQUE D'UN ANTI-ANDROGENE ET DE TAMOXIFENE POUR OBTENIR UN EFFET ANTI-ANDROGENIQUE ET UNE INHIBITION D'AROMATASE
Abstract: front page image
(EN)The present invention relates to a pharmaceutical product, daily dose or dose regimen comprising an anti-androgen and tamoxifen, wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or pharmaceutically acceptable salt or solvate thereof. The invention also relates to a method of providing an anti-androgenic effect and anti-oestrogenic effect in a patient, wherein the anti-oestrogenic effect is provided substantially without causing an additional increase in the levels of circulating androgens.
(FR)L'invention concerne un produit pharmaceutique à dose journalière ou schéma posologique, qui contient un anti-androgène et du tamoxifène. L'anti-androgène est sélectionné dans le groupe comprenant flutamide, nilutamide, acétate de chlormadinone et cyprotérone ou un sel ou solvate pharmaceutiquement acceptable de ceux-ci. L'invention concerne aussi un procédé permettant d'obtenir un effet anti-androgénique et un effet anti-oestrogénique chez un patient, l'effet anti-oestrogénique étant obtenu sensiblement sans augmentation supplémentaire des taux d'androgènes circulants.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)